About Us

Our Group

ceo quote

"As one of the oldest pharmaceutical companies in the world, we take pride in our heritage with a keen eye for the future defined by an unwavering commitment for patient cause."

Elcin Barker Ergun
MENARINI GROUP CEO

High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with 135 years of history. Founded in 1886 in Naples under the name of Farmacia Internazionale, in 1915 Menarini moved to Florence where the Group’s headquarters are still located today.

The Menarini Group is present in 140 countries around the world. Its companies span from Europe to Asia, to Africa and the Middle East, to Central America and to the United States where with the acquisition of Stemline Therapeutics, a NASDAQ-listed biopharmaceutical company, the company marked its entry into the US oncology market.

Thanks to the valuable contribution of over 17,000 employees, every year almost 600 million packs of drugs are produced at the Group's 18 manufacturing sites including a biotech plant for the manufacturing of monoclonal antibodies that also serves external clients. Our drugs are distributed across 6 continents for the treatment of pathologies in cardiology, pneumology, inflammation and gastroenterology.

Menarini invests in the future and guarantees drug availability in the present for the improvement of patient health and well-being.

In its 10 Research & Development centers, Menarini’s main focus is dedicated to therapeutic areas with unresolved pathologies, such as oncology and anti-infectives (AMR), where increasing treatment options is fundamental to helping those in need. The Group's pipeline concentrates on innovative drugs and technologies including both small molecule and biologics for hematologic and solid tumors for greater personalized solutions.

The Group has also invested in diagnostics to develop instruments with high speed and precision for diagnoses in various fields such as clinical chemistry, diabetes, immunology, hematology, histology and point-of-care. In addition, Menarini is developing advanced technologies for the analysis of rare tumor cells with single cell precision.

From research to manufacturing, from distribution to scientific information, Menarini's goal is to achieve excellence.

Governance

Consolidated Turnover

consolidated turnover

Our history

Discover our milestones since 1886: the origins, the international expansion step by step and the recent acquisitions.

Read More

Our history


Our values

Our values

Everyday we put our values into action. 4 values, which have given life to Menarini and have shaped its history.

Read More

Our values

Menarini receives the coveted M&A Award 2021 for the 2020 acquisition of US company Stemline Therapeutics

Florence, 14th May 2021 - Menarini Group takes home the prestigious  M&A Award 2021 for the “Italy acquires Abroad“ category in recognition of their landmark...

Covid-19: Menarini, new reagent made in Italy for the isolation of viral RNA

Florence, 16 April 2021 - Menarini Diagnostics, a company of the Menarini Group, launches Leasy Kit, an innovative reagent, result of its own research and 100% "made in Italy,"...

Menarini Pills of Art Junior project launched, video clips made by the younger generations for children and teenagers

Watchword: getting the younger generations talking about art. Following on from the success of the Menarini Pills of Art




Search Menarini in the world

v

Etiam commodo dui eget wisi. Donec iaculis gravida nulla. Donec quis nibh at felis congue commodo. Etiam bibendum elit eget erat.

Menarini Pills of Art

Discover our initiative which confirms the company’s affiliation with art.

Read More

fondazione internazionale menarini

a meeting point for all friends with common ideals towards the progress of sciences for the benefit of mankind.

sergio gorini, foundation’s first president

read more

>